SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Tatva Chintan Pharma - Quaterly Results

04 Aug 2023 Evaluate
The company witnessed a 23.28% growth in the revenue at Rs. 1061.05 millions for the quarter ended June 2023 as compared to Rs. 860.65 millions during the year-ago period.The Net Profit of the company registered a slight decline of -2.96% to Rs. 82.48  millions from Rs. 85.00 millions.OP of the company witnessed a marginal growth to 206.28 millions from 153.73 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 1061.05 860.65 23.28 1061.05 860.65 23.28 4030.44 4278.11 -5.79
Other Income 10.15 18.75 -45.87 10.15 18.75 -45.87 56.78 106.29 -46.58
PBIDT 206.28 153.73 34.18 206.28 153.73 34.18 603.56 1163.97 -48.15
Interest 28.98 10.64 172.37 28.98 10.64 172.37 83.84 49.51 69.34
PBDT 177.30 143.09 23.91 177.30 143.09 23.91 483.85 1114.46 -56.58
Depreciation 60.11 23.33 157.65 60.11 23.33 157.65 95.54 81.80 16.80
PBT 117.19 119.76 -2.15 117.19 119.76 -2.15 388.31 1032.66 -62.40
TAX 34.71 34.76 -0.14 34.71 34.76 -0.14 -16.34 72.79 -122.45
Deferred Tax 14.31 3.73 283.65 14.31 3.73 283.65 -35.93 -107.29 -66.51
PAT 82.48 85.00 -2.96 82.48 85.00 -2.96 404.65 959.87 -57.84
Equity 221.65 221.65 0.00 221.65 221.65 0.00 221.65 221.65 0.00
PBIDTM(%) 19.44 17.86 8.84 19.44 17.86 8.84 14.98 27.21 -44.96

Tatva Chintan Pharma Share Price

1275.10 -8.55 (-0.67%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
BASF India 3703.10
Tata Chemicals 709.05
SRF 2493.65
Pidilite Inds. 1393.25
Deepak Nitrite 1538.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×